Direct evidence is thin. The claim is plausible and aligns with adjacent findings, but there isn't yet a body of high-quality work that would let us call it well-supported on its own terms.
do you believe that you would see a change in the methylation pattern pre and post Ramy absolutely but but I think what you're really asking is would we would we see a change in the methylation pattern that is what people are calling a reversal of biological aging I don't know if that's what you're asking
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
I don't know if that's what you're asking so there's no question it's exactly where I'm going which is given our shared interest in that topic as well which is you know when what is Ramy effectively doing that is it rewriting the epig genome is it undoing some of the Aging of the te- cell and is it writing that code via methylation onto the epome yeah I don't have a strong feeling
I'm I don't have such a strong feeling that rap ayon would reverse what people are calling the epigenetic Aging clock universally I think in some contexts it will in tea cells in particular
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.